You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CR011-vcMMAE

Showing 1 - 25 of 917
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 Trial in United States (Glembatumumab Vedotin, Laboratory Biomarker

Completed
Has Results
  • Recurrent Uveal Melanoma
  • Stage IV Uveal Melanoma AJCC v7
  • Glembatumumab Vedotin
  • +2 more
  • Phoenix, Arizona
  • +24 more
Jul 30, 2020

Recurrent Osteosarcoma Trial in Canada, Puerto Rico, United States (Glembatumumab Vedotin, Laboratory Biomarker Analysis,

Completed
Has Results
  • Recurrent Osteosarcoma
  • Glembatumumab Vedotin
  • +2 more
  • Birmingham, Alabama
  • +154 more
Jan 6, 2022

Squamous Cell Carcinoma of the Lung Trial in United States (Phase I: Glembatumumab Vedotin, Phase II: Glembatumumab Vedotin)

Terminated
Has Results
  • Squamous Cell Carcinoma of the Lung
  • Phase I: Glembatumumab Vedotin
  • Phase II: Glembatumumab Vedotin
  • Miami, Florida
  • +9 more
Jun 21, 2019

Advanced Malignant Solid Tumor, Estrogen Receptor Negative, GPNMB Positive Trial (drug, biological, other)

Withdrawn
  • Advanced Malignant Solid Neoplasm
  • +17 more
  • Glembatumumab Vedotin
  • +4 more
  • (no location specified)
Jul 17, 2018

Breast Cancer Trial in Italy (Ribociclib, Letrozole, Alpelisib)

Active, not recruiting
  • Breast Cancer
  • Casale Monferrato, AL, Italy
  • +40 more
Dec 3, 2021

Advanced Breast Cancer Trial in Worldwide (Ribociclib, fulvestrant, Ribociclib )

Active, not recruiting
Has Results
  • Advanced Breast Cancer
  • Mobile, Alabama
  • +173 more
Aug 4, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • (no location specified)
Nov 22, 2023

Solid Tumor, Adult Trial in Shanghai (3D011-08)

Recruiting
  • Solid Tumor, Adult
  • Shanghai, Floor 2, Building 2, 270 Dong 'an Road, Xuhui District, China
    Fudan University Shanghai Cancer Center
Jan 2, 2023

Unresectable Angiosarcoma Trial in Tokyo (BNCT)

Recruiting
  • Unresectable Angiosarcoma
  • BNCT
  • Tokyo, Japan
    National Cancer Center Hospital
Nov 21, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Solid Tumor, Adult Trial in Orlando, Cincinnati (ADA-011, PD(L)-1 inhibitor)

Recruiting
  • Solid Tumor, Adult
  • Orlando, Florida
  • +1 more
Jan 6, 2023

Small Cell Lung Cancer Trial in Worldwide (ABBV-011, Budigalimab)

Recruiting
  • Small Cell Lung Cancer
  • Birmingham, Alabama
  • +32 more
Oct 5, 2022

NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Dec 7, 2022

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Advanced, Metastatic Breast Cancer Trial in Worldwide (LEE011, Letrozole, LEE011 Placebo)

Active, not recruiting
Has Results
  • Advanced, Metastatic Breast Cancer
  • Chandler, Arizona
  • +222 more
Dec 3, 2021

Molecular Evaluation Instrument for Lung Cancer Diagnosis and

Not yet recruiting
  • Lung Cancer
    • (no location specified)
    Oct 11, 2023

    Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

    Recruiting
    • Gastric Cancer
    • HER2-low-expressing Gastric Cancer
    • Shanghai, China
      Shanghai East Hospital
    Oct 9, 2023

    Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (ribociclib, Paclitaxel, Carboplatin)

    Completed
    • Ovarian Cancer
    • +2 more
    • Ann Arbor, Michigan
    • +7 more
    Sep 1, 2022

    Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee Trial in United States (Cebranopadol (GRT6005) Low-Dose Range,

    Completed
    • Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
    • Cebranopadol (GRT6005) Low-Dose Range
    • +3 more
    • Birmingham, Alabama
    • +82 more
    Jul 13, 2021

    Triple Negative Breast Tumors Trial in Worldwide (ladiratuzumab vedotin, Pembrolizumab)

    Recruiting
    • Triple Negative Breast Neoplasms
    • Birmingham, Alabama
    • +49 more
    Jan 4, 2023

    Pancreatic Fistula Trial in Cairo (pancreaticoduodenectomy procedure)

    Completed
    • Pancreatic Fistula
    • pancreaticoduodenectomy procedure
    • Cairo, Egypt
      Qena faculty of Medicine, South Valley University
    Jan 8, 2023

    Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

    Recruiting
    • Recurrent Follicular Lymphoma
    • Refractory Follicular Lymphoma
    • Bendamustine Hydrochloride
    • Brentuximab Vedotin
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Dec 17, 2021

    Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

    Active, not recruiting
    • Recurrent Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Brentuximab Vedotin
    • +4 more
    • Duarte, California
      City of Hope Medical Center
    Feb 17, 2022

    Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)

    Not yet recruiting
    • Recurrent Endometrial Serous Adenocarcinoma
    • Biospecimen Collection
    • +4 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    May 12, 2023

    Lymphoma, Solid Tumor Trial in Buffalo (Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study)

    Terminated
    • Lymphoma
    • Solid Neoplasm
    • Gemcitabine Hydrochloride
    • +3 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jul 20, 2022